Taysha Gene Therapies (NASDAQ:TSHA) Price Target Cut to $7.00 by Analysts at Piper Sandler

Taysha Gene Therapies (NASDAQ:TSHA) had its price target cut by stock analysts at Piper Sandler from $9.00 to $7.00 in a research note issued to investors on Monday, Benzinga reports. The brokerage presently has an “overweight” rating on the stock. Piper Sandler’s target price indicates a potential upside of 212.50% from the company’s previous close.

A number of other equities research analysts have also recently issued reports on the company. JMP Securities restated a “market outperform” rating and issued a $5.00 price objective on shares of Taysha Gene Therapies in a research note on Thursday, June 20th. BMO Capital Markets started coverage on Taysha Gene Therapies in a research note on Thursday. They issued an “outperform” rating and a $5.00 price objective on the stock. Canaccord Genuity Group reiterated a “buy” rating and set a $7.00 price target on shares of Taysha Gene Therapies in a research report on Thursday, March 21st. Jefferies Financial Group reiterated a “buy” rating and set a $8.00 price target (up from $2.00) on shares of Taysha Gene Therapies in a research report on Tuesday, May 14th. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $7.00 price objective on shares of Taysha Gene Therapies in a research report on Thursday, June 20th. Ten research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $6.60.

Taysha Gene Therapies Price Performance

TSHA opened at $2.24 on Monday. The company has a debt-to-equity ratio of 0.75, a current ratio of 3.38 and a quick ratio of 3.38. The company has a market capitalization of $418.92 million, a price-to-earnings ratio of -4.57 and a beta of 0.42. The firm’s fifty day moving average price is $2.97 and its two-hundred day moving average price is $2.42. Taysha Gene Therapies has a 1 year low of $0.58 and a 1 year high of $4.32.

Taysha Gene Therapies (NASDAQ:TSHA) last posted its quarterly earnings data on Tuesday, May 14th. The company reported ($0.10) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.01. The firm had revenue of $3.41 million for the quarter, compared to the consensus estimate of $3.70 million. Taysha Gene Therapies had a negative net margin of 833.60% and a negative return on equity of 782.81%. During the same period in the previous year, the firm earned ($0.28) EPS. As a group, analysts anticipate that Taysha Gene Therapies will post -0.43 earnings per share for the current fiscal year.

Institutional Trading of Taysha Gene Therapies

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Howard Capital Management Inc. bought a new position in shares of Taysha Gene Therapies in the fourth quarter worth approximately $25,000. Victory Capital Management Inc. bought a new stake in Taysha Gene Therapies in the fourth quarter valued at $28,000. Dynamic Technology Lab Private Ltd bought a new stake in Taysha Gene Therapies in the fourth quarter valued at $31,000. China Universal Asset Management Co. Ltd. bought a new stake in Taysha Gene Therapies in the fourth quarter valued at $38,000. Finally, Cannon Global Investment Management LLC bought a new stake in Taysha Gene Therapies in the first quarter valued at $69,000. Hedge funds and other institutional investors own 77.70% of the company’s stock.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.